About 1,170 results
Jan 25, 2010 by Public Health Agency of Canada
Tyring and colleagues conducted a randomized, double-blinded comparison of two different dosages of live attenuated injectable Oka/Merck herpes zoster vaccine (58,000 vs. 207,000 pfu/0.65mL dose) in 698 adults aged 50 ...
Dec 13, 2010 by Jun, G., Naj, A. C., Beecham, G. W., Wang, L.-S., Buros, J., Gallins, P. J., Buxbaum, J. D., Ertekin-Taner, N., Fallin, M. D., Friedland, R., Inzelberg, R., Kramer, P., Rogaeva, E., St. George-Hyslop, P., Arnold, S. E., Baldwin, C. T., Barber, R., Beach, T., Bigio, E. H., Bird, T. D., Boxer, A., Burke, J. R., Cairns, N., Carroll, S. L., Chui, H. C., Clark, D. G., Cotman, C. W., Cummings, J. L., DeCarli, C., Diaz-Arrastia, R., Dick, M., Dickson, D. W., Ellis, W. G., Fallon, K. B., Farlow, M.
While this article was being prepared for publication, a GWAS on AD was reported by Seshadri et al.39 There was some overlap in that study and ours in that the Translational Genomics Research Institute and Framingham Heart Study ....
Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co, Medpace Inc, Merck and Co Inc, Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc Inc, and Wyeth.
Jun 14, 2012 by vsubbiah
Targeted agents have revolutionized the therapeutic landscape of many cancers, beginning with imatinib for Bcr-Abl-positive chronic myeloid leukemia (Kantarjian et al., 2002) and c-kit-positive gastrointestinal stromal tumor (Demetri et al., 2002)
.... The key to deciphering these questions is to use next-generation deep sequencing to profile responders versus non-responders, and to perform a trial that incorporates IGF1R inhibitors early in the course of the disease.
Oct 5, 2011 by Giovanni Nardo et al.
Citation: Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, et al. (2011) Amyotrophic Lateral Sclerosis .... Validation of the 14 selected protein biomarkers versus healthy controls and non-ALS neurological controls: statistical analysis.
Validation on single PBMC ..... PBMC proteins were obtained by cell lysis in 50 mM Tris-HCl, pH 7.5, 2% (w/v) CHAPS, 37.5 U benzonase (Merck), supplemented with Protease Inhibitors (Sigma). Proteins were quantified by the ...
Dec 4, 2012 by Guo Y, Lip GH, Apostolakis S.
Aviles et al. (11) were the first to demonstrate that elevated CRP predicted increased risk of developing AF in a large population-based prospective cohort including 5,806 patients. In another large cohort study of 47,000 subjects, .... sex, race,
hypertension, CHF, statin, and ACEI/ARB use 2. CRP and IL-6 level did not remain higher in persistent versus paroxysmal group after adjusting for rhythm present during blood draw. Pellegrino et al. (24), 2011, 96 AF 60 Controls ...
Mar 28, 2012 by email@example.com (David A. Antonetti et al)
In a combined analysis of data from two clinical trials of oral ruboxistaurin, the proportion of patients with sustained moderate visual loss was smaller in the group of patients who received ruboxistaurin than in the placebo group (6.1% vs. ....
Novartis, Eli Lilly, Merck, Sanofi Aventis, GlaxoSmithKline, Pfizer, Genentech, Takeda, Comentis, and Allegan; and Dr. Gardner, consulting fees from Genentech, GlaxoSmithKline, Apogee Biotechnology, and Merck and payment for ...
Mar 19, 2013 by Aneja A, Esquitin R, Shah K, et al.
... cardiovascular trials. Secondary aims included assessment of trial outcomes by source of funding, conflict of interest subtype (detailed in the following text), and trial endpoints (clinical vs. surrogate). ..... Licurse A., Barber E., Joffe S., Gross C.;
The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Intern Med. 2010 .... Hirsch L.J.; Conflicts of interest in drug development: the practices of Merck & Co., Inc.. Sci Eng Ethics. 2002 ...
Feb 5, 2011 by nirityarom
Their EGFR IHC staining interpretation categorizes tumors as increased (EGFRi; tumors scoring higher at the invasive margin compared to central parts) vs. non-increased (EGFRn; tumors with equal or lower score at the invasive margin
compared ... Activating EGFR catalytic domain mutations are rare in Caucasian patients with colorectal cancer (0.34%; 1/293) and do not seem to confer sensitivity to gefitinib and chemotherapy (Barber et al., 2004; Ogino et al., 2005).
Nov 2, 2010 by Kirsten M.L. Hertoghs, Perry D. Moerland, Amber van Stijn, Ester B.M. Remmerswaal, Sila L. Yong, Pablo J.E.J. van de Berg, S. Marieke van Ham, Frank Baas, Ineke J.M. ten Berge, René A.W. van Lier
In effector LCMV-specific CD8+ T cells in mice, Wherry et al. observed a similar increase in Anxa1 and Anxa2 (34), which suggests these genes exert a conserved function in signal transduction in virus-primed CD8+ T cells. Although a number of
changes ...... In case multiple mouse probesets were found for a given human probe, we selected the probeset with the largest absolute fold change versus naive for the condition of interest. Immunofluorescent staining and ...
Oct 6, 2013 by Rolf-Alexander Düring
The first findings of pharmaceuticals, an important group of anthropogenic compounds, in the environment occurred in the 1970s (e.g., by Garrison et al.  and Hignite et al. ). Since then, pharmacologically ..... For preconcentration and
cleanup, Oasis HLB (60 mg, 3 mL) SPE cartridges conditioned with 5 mL methanol and equilibrated with 5 mL Milli-Q (Merck Millipore, Darmstadt, Germany) water were used. The samples of raw waste water (stored at -32°C) were ...